Using Natriuretic Peptides for Selection of Patients in Acute Heart Failure Clinical Trials
Autor: | Alexandre Mebazza, Bertram Pitt, Lothar Roessig, Robert J. Mentz, Mihai Gheorghiade, Sakima A. Smith, Dan Longrois, Faiez Zannad, Javed Butler, William T. Abraham |
---|---|
Přispěvatelé: | Ohio State University [Columbus] (OSU), Duke University Medical Center, Bayer Pharma AG [Berlin], Service d'Anesthésie-Réanimation [AP-HP Hôpitaux Saint-Louis Lariboisière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Lariboisière-Fernand-Widal [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service d'anesthésie - réanimation chirurgicale [CHU Bichat], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), Center for Cardiovascular Innovation, Feinberg School of Medicine, Northwestern University [Evanston]-Northwestern University [Evanston], University of Michigan [Ann Arbor], University of Michigan System, Service de Cardiologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Défaillance Cardiovasculaire Aiguë et Chronique (DCAC), Université de Lorraine (UL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Stony Brook University [SUNY] (SBU), State University of New York (SUNY), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Lariboisière-Université Paris Diderot - Paris 7 (UPD7), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris]-Université Paris Diderot - Paris 7 (UPD7), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Université Paris Diderot - Paris 7 (UPD7)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris] |
Jazyk: | angličtina |
Rok vydání: | 2015 |
Předmět: |
medicine.medical_specialty
MESH: Clinical Trials as Topic Population [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system Humans Medicine In patient Hypertensive emergency MESH: Patient Selection MESH: Natriuretic Peptides Natriuretic Peptides education Intensive care medicine Heart Failure Clinical Trials as Topic education.field_of_study MESH: Humans business.industry Patient Selection Cardiogenic shock Pulmonary edema medicine.disease 3. Good health Clinical trial Heart failure Acute Disease MESH: Heart Failure Biomarker (medicine) MESH: Acute Disease Cardiology and Cardiovascular Medicine business |
Zdroj: | American Journal of Cardiology American Journal of Cardiology, Elsevier, 2015, 116 (8), pp.1304-1310. ⟨10.1016/j.amjcard.2015.07.049⟩ |
ISSN: | 0002-9149 1879-1913 |
DOI: | 10.1016/j.amjcard.2015.07.049⟩ |
Popis: | International audience; Acute heart failure (AHF) is a complex syndrome with presentations ranging from hypotensive cardiogenic shock to hypertensive emergency with pulmonary edema. Most patients with AHF present with worsening of chronic HF signs and symptoms over days to weeks, and significant heterogeneity exists. It can, therefore, be challenging to characterize the overall population. The complexity of defining the AHF phenotype has been cited as a contributing cause for neutral results in most pharmacologic trials in patients with AHF. Dyspnea has been a routine inclusion criterion for AHF for over a decade, but the utility of current instruments for dyspnea assessment has been called into question. Furthermore, the threshold of clinical severity that prompts patient admission of an HF clinic visit may vary substantially across regions in global trials. Therefore, the inclusion of cardiac-specific biomarkers has been incorporated into AHF trials as 1 strategy to support inclusion of the target patient population and potentially enrich the population with patients at risk for clinical outcomes. In conclusion, we discuss strategies to support appropriate patient selection in AHF trials with an emphasis on using biomarker criteria that may improve the likelihood of success with future AHF clinical trials. |
Databáze: | OpenAIRE |
Externí odkaz: |
načítá se...